Trovafloxacin was selective for RSK4 in an in vitro screen of 140 kinases and silencing of RSK4 reduced the ability of trovafloxacin to enhance cisplatin-induced apoptosis in the lung cancer line, A549. Here, RPS6KA6 is linked to lung cancer.